Tolga Tanguler compensation by year
ALNYLAM PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held| Component | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $547,900 | $603,200 | $627,400 | $698,000 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $1,500,110 | $950,050 | $725,000 | $3,687,650 |
| Option awards | $4,501,220 | $948,360 | $722,900 | $940,050 |
| Non-equity incentive | $316,250 | $352,280 | $659,400 | $783,200 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $11,710 | $15,820 | $19,870 | $20,120 |
| Total | $6,877,190 | $2,869,710 | $2,754,570 | $6,129,020 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ALNYLAM PHARMACEUTICALS, INC. DEF 14A filed April 6, 2026, accession 0001628280-26-023923, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ALNYLAM PHARMACEUTICALS, INC. filed document, accession 0001628280-26-023923. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 15,482 | $6,156,417 | — |
| RSU | 14,137 | $5,621,578 | — |
| RSU | 7,000 | $2,783,550 | — |
| RSU | 3,800 | $1,511,070 | — |
| RSU | 3,167 | $1,259,358 | — |
| RSU | 1,666 | $662,485 | — |
| Option | 3,235 | — | $190.01 |
| Option | 1,151 | — | $147.47 |
| Option | 5,220 | — | $152.61 |
| Option | 7,819 | — | $243.53 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ALNYLAM PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments ALNYLAM PHARMACEUTICALS discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Death | $0 | $10,987,266 | $0 | $10,987,266 |
| Disability | $0 | $10,987,266 | $0 | $10,987,266 |
| Voluntary resignation | $0 | $0 | $0 | $0 |
| Change in control and involuntary termination | $1,655,400 | $18,360,095 | $48,320 | $20,063,815 |
| Retirement | $0 | $0 | $0 | $0 |
| Involuntary for cause | $0 | $0 | $0 | $0 |
Per the Potential Payments Upon Termination or Change in Control table in ALNYLAM PHARMACEUTICALS, INC.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
ALNYLAM PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Yvonne Greenstreet | Chief Executive Officer | $14,867,600 |
| Jeffrey Poulton | Executive Vice President, Chief Financial Officer | $6,863,800 |
| Bryan Supran | Executive Vice President, Chief Legal Officer and Secretary | $6,846,350 |
| Pushkal Garg | Executive Vice President, Chief Research and Development Officer | $6,490,500 |
| Tolga Tanguler · this page | Executive Vice President, Chief Commercial Officer | $6,129,020 |
Tolga Tanguler's compensation dossier, ALNYLAM PHARMACEUTICALS
You have read Tolga Tanguler's totals and holdings. The dossier adds each equity grant ALNYLAM PHARMACEUTICALS disclosed for Tolga Tanguler and ALNYLAM PHARMACEUTICALS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full ALNYLAM PHARMACEUTICALS compensation record
free company briefThis page is one person within ALNYLAM PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ALNYLAM PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ALNYLAM PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ALNYLAM PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ALNY
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.